No marked variation in mitochondrial ROS generation post-pioglitazone or rosiglitazone treatment was observed in CGD cases with varying germline mutations (Figure 3B), indicating that PPARγ-induced mitochondrial ROS production is independent of the NADPH oxidase. Here, PPARG is linked to chronic granulomatous disease.